Biosenic: partnership with Phebra PTY evolves

(CercleFinance.com) - BioSenic is up almost 4% on the Paris Bourse on Monday, after signing an agreement to develop the first oral formulation of its experimental treatment for chronic graft-versus-host disease (cGvHD).


The company, which specializes in clinical trials for severe autoimmune and inflammatory diseases and cell therapy, reports that its subsidiary Medsenic has signed an agreement with Australia's Phebra PTY to adapt the agreement signed in 2021.

Whereas the original licensing agreement provided for a 100% net profits commercialization agreement for Medsenic, mainly in Europe, and 55% net sales profits for Phebra in the rest of the world, it now provides for the payment of a 2% royalty on worldwide sales, in order to simplify the conditions for sub-licensing to new external partners.

In addition, as part of the licensing agreement, Phebra has agreed to grant Medsenic exclusive worldwide territorial rights for the use of its lead product in GvHD.

At BioSenic, we emphasize that the evolution of the agreement is very favorable to the development of the business and increased interest from new investors to contribute to the success of our core project.

The radical improvement of the commercial agreement between Phebra PTY and Medsenic should thus facilitate the task of putting in place all the necessary financing for the Phase 3 clinical trial in cGvHD, a program whose success is considered 'key' to the company's success.

Copyright (c) 2024 CercleFinance.com. All rights reserved.